About Adjuvance Technologies
Headquartered in Lincoln, Nebraska, Adjuvance is a privately held clinical-stage biopharmaceutical company. We are driven by a mission to empower health through fundamental advances in adjuvant design, vaccine development, and manufacturing. Our team of scientists, researchers and clinicians have developed the ability to synthesize next generation saponin adjuvants and are using them as the basis of developing new combination adjuvants and new adjuvanted vaccines.
Adjuvance is pursuing internal development of high-value disease vaccines, including a shingles vaccine. Shingles vaccination is recommended for everyone over 50 years of age in the United States and represents a market of over $2 billion in 2020. Increases in the proportion of the population vaccinated and a growing population over 50 will fuel future growth. The shingles vaccine is differentiated by our proprietary adjuvant, TQL-1055.
TQL-1055, is a rationally designed, novel analogue of the saponin adjuvant QS-21. TQL-1055 is designed to have improved tolerability after vaccination and the same strong improvement in immune response compared to QS-21. With TQL-1055 as the foundation, Adjuvance is designing new combination adjuvants to produce different types of immune responses. TQL-1055 is in clinical development, with plans for multiple indications; our combination adjuvants are designed for use in infectious disease, oncology, neurobiology, substance abuse, and allergy.
Adjuvance’s business model, dedication to global health advances and vaccine access, creates an opportunity for important partnerships. Through partnering, Adjuvance wishes to extend its adjuvant technology to global vaccine developers and immune-oncology companies through out-licensing.
Adjuvance was founded in 2009, to commercialize the research and intellectual property developed at Memorial Sloane Kettering Cancer Center in New York. The company has received $3.5 million in grants from the U.S. National Institutes of Health to conduct pre-clinical research in pertussis, influenza, tuberculosis, and COVID-19 vaccine development. After raising seed money through dedicated angel investors, Adjuvance received $20 million in Series A financing from Morningside Venture Investors in August 2019.
Industry Leading Vaccine Development
Adjuvance Technologies is applying its adjuvant technology to important vaccine development programs, focusing on targets in infectious disease and substance abuse. Adjuvance is in pre-clinical development on a shingles vaccine that uses TQL-1055 in a combination adjuvant. During 2022, Adjuvance will enter a Phase 1/2 clinical trial with this improved shingles vaccine. In early 2021, Adjuvance conducted its first human clinical trial, the Pertussis Acellular Vaccine Adjuvanted (PAVA) trial using TQL-1055.
Adjuvants at the Core
Adjuvance Technologies is innovating adjuvant design and manufacturing—and partnering with leading vaccine developers. Through these out-licensing partnerships, vaccine developers benefit from our next-generation adjuvants to advance vaccines in multiple therapeutic areas including infectious disease, oncology, allergy, and neurobiology. Adjuvance has initiated partnerships with more than 20 companies and academic institutions exploring the use of its adjuvants. Read more about adjuvants and our adjuvants.
Contact Us for more information on partnerships with Adjuvance.